Clinical Trials Logo

Primary Immune Thrombocytopenia clinical trials

View clinical trials related to Primary Immune Thrombocytopenia.

Filter by:

NCT ID: NCT04225156 Active, not recruiting - Clinical trials for Primary Immune Thrombocytopenia

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

ADVANCE+
Start date: June 2, 2020
Phase: Phase 3
Study type: Interventional

This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.

NCT ID: NCT04224688 Terminated - Clinical trials for Primary Immune Thrombocytopenia

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

myOpportunITy2
Start date: June 3, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

NCT ID: NCT04200456 Terminated - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

myOpportunITy1
Start date: January 31, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

NCT ID: NCT04188379 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

ADVANCE
Start date: December 16, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

NCT ID: NCT04100876 Not yet recruiting - Clinical trials for Primary Immune Thrombocytopenia

Effect of DNMT SNPs on DNA Methylation in Primary ITP

Start date: December 1, 2019
Phase:
Study type: Observational

- To compare global DNA methylation status between ITP patients and healthy subjects . - To determine the effect of DNMT3A −448 G/A SNP variant A allele and DNMT3B −149C/T SNP variant T-allele on global DNA methylation in both ITP patients and healthy control subjects.

NCT ID: NCT03771378 Recruiting - Clinical trials for Primary Immune Thrombocytopenia

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

(ITP;rhTPO)
Start date: January 16, 2019
Phase: Phase 4
Study type: Interventional

Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. In most cases, platelet count is negatively correlated with the severity of bleeding. Correcting low platelets is the main measure to prevent bleeding in patients with ITP. Both rhTPO and eltrombopag act on TPO receptors to increase platelets.Which one will have a better short-term (2 weeks) effect to improve platelets is the purpose of the investigator's research.

NCT ID: NCT03275740 Terminated - Healthy Clinical Trials

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Start date: July 17, 2017
Phase: Phase 1
Study type: Interventional

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be evaluated.

NCT ID: NCT03102593 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia.

NCT ID: NCT01727232 Completed - Clinical trials for Primary Immune Thrombocytopenia

Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Start date: January 2007
Phase: N/A
Study type: Observational

The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .